Men diagnosed after prostatectomy with seminal vesicle invasion often have external beam irradiation (EBRT) as adjuvant treatment. Typically, men treated with radiation do not have assessment or treatment for T3b because it is often not detected. We report our results of seminal vesicle biopsy (SVB) in men with higher risk features planning to undergo permanent seed implant (PSI) followed by EBRT.
INTRODUCTION AND OBJECTIVES:
Men diagnosed after prostatectomy with seminal vesicle invasion often have external beam irradiation (EBRT) as adjuvant treatment. Typically, men treated with radiation do not have assessment or treatment for T3b because it is often not detected. We report our results of seminal vesicle biopsy (SVB) in men with higher risk features planning to undergo permanent seed implant (PSI) followed by EBRT.
METHODS: Of 1981 men who treated by PSI and followed 5-22 years (mean 10), 615 (31%) with high risk features had 6 TRUS guided biopsies of the SV (3 from each side). Patients with +SVB underwent laparoscopic pelvic lymph node dissection and those with positive nodes, bone or CT scans were excluded from implantation. 3 months of hormone therapy (NHT) was followed by Pd-103 implant to the prostate (dose 100 Gy) and proximal SV and 2 months later 45 Gy of conformal or image guided EBRT to prostate and SV only. NHT was given a median of 9 months. Within 2 months after treatment CT-based dosimetry was done with radiation doses converted to the biologic effective dose (BED). Biochemical freedom from failure (BFFF) was computed by the Phoenix definition, freedom from metastasis (FFM) in men with BF by absence of a positive bone or CT scan and causespecific survival (CSS) by freedom from death in men with clinical recurrence. Association of risk features to +SVB were compared by chisquare and linear regression (LR). Survival was computed by KaplanMeier estimates with comparisons by log rank and Cox hazard rates (HR).
RESULTS: 53/615 (9.4%) had +SVB. Higher stage, Gleason score (GS) and PSA were associated with a positive SVB (p<0.001). LR demonstrated significance for stage (p<0.001) and GS (p¼0.001). BED was higher in patients receiving a SV implant (202. Vs. 179.3 Gy2, p<0.001 89. 6%, 96.5 vs. 84.4% and 94.9 vs. 75% (p<0.001) and for CSS was 99.6 vs. 97.8%, 96.4 vs. 82.1% and 91.3 vs. 65.7% (p<0.001 CONCLUSIONS: Men who have pT3b disease have inferior BFFF, FFM and CSS. Advanced stage and high GS are highly associated with a +SVB. Higher radiation dose is associated with improved CSS in the pT3b patients. Taken together these data suggest SVB should be performed in men presenting with high GS and stage when considering combination radiation therapy. When performing PSI, implantation of the SVs will increase dose and improve long-term cause-specific survival.
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MP05-06 LONG-TERM SURVIVAL IN MEN WITH GLEASON SCORE 9-10 TREATED WITH PROSTATE BRACHYTHERAPY AND EXTERNAL BEAM IRRADIATION
Nelson Stone*, Richard Stock, New York, NY INTRODUCTION AND OBJECTIVES: Very high grade prostate cancer is associated with poor outcomes. We report on the long-term outcomes of men with Gleason score (GS) 9-10 prostate cancer treated by prostate brachytherapy (PSI) and external beam irradiation (EBRT).
METHODS: Of 1981 men who were treated by PSI and followed 5-22 years (mean 10), GS was 6 in 1304 (65.8%), 7 in 466 (23.5%), 8 in 142 (7.2%) and 9-10 in 69 (3.5%). Men with positive bone or CT scans were excluded from implantation. 3 months of hormone therapy (NHT) was followed by Pd-103 implant to the prostate (dose 100 Gy) and 2 months later 45 Gy of conformal or image guided EBRT. NHT was given a median of 9 months. Within 2 months after treatment CT-based dosimetry was done with radiation doses converted to the biologic effective dose (BED). Biochemical freedom from failure (BFFF) was computed by the Phoenix definition, freedom from metastasis (FFM) in men with BF by absence of a positive bone or CT scan and cause-specific survival (CSS) by freedom from death in men with clinical recurrence. Association of risk features to GS 9-10 were compared by chi-square and linear regression (LR). Survival was computed by Kaplan-Meier estimates with comparisons by log rank and Cox hazard rates (HR).
RESULTS: Mean age was 65.6 years (median 66, range 39-85); mean PSA was 9.4 ng/ml (median 6.7, range 0.3-300) and mean BED 194.6 Gy (median 200, range 15-299). Median BED for GS9-10 was 199 Gy2. BFFF, FFM and CSS by GS are shown in the table. The mean survival time for the 4 GS groups was: 1) 21.5 years (95%CI 21.2-21.8), 2) 19.2 years (95%CI 18.6-19.7), 3) 18.1 years (95%CI 17.2-19.1) and 4) 13.9 years (95%CI 13.1-14.8, p<0.001). Only clinical stage was associates with CSS with 15-year survival for T2a 100%, T2b-c 40.5% and T3 0% (p¼0.025). Cox HR for CSS was significant for stage (p¼0.055, HR 2.0) and BED (p¼0.081, HR 0.985).
CONCLUSIONS: PBI combined with EBRT has excellent 15-year survival in men with GS 9-10 and clinical stage T2a. While 68% of men with T3 GS9-10 are alive at 10 years, at 15-year survival was 0. These men should be considered for alternate treatment strategies, possibly with early systemic therapy. METHODS: A retrospective analysis was performed on a prospectively maintained database of patients receiving BT AE external beam radiation therapy (EBRT) AE hormone therapy (HT) for NCCN low, intermediate or high-risk prostate cancer at a single institution between 1990-2011 with a minimum follow-up of 5 years. Patients were categorized as receiving no HT (n¼438, 41.6%), 6 months (n¼317, 31.1%) or > 6 months (n¼298, 28.3%) of HT. Those receiving combination HT within one year of final testosterone (T) measurement were excluded, as well as patients receiving salvage ADT at any time. 5 and 10-year freedom from persistent hypogonadism (T<280 ng/dL) and castration (T<50 ng/dL) for each group was evaluated with KaplanMeier estimates. Multivariable cox proportional hazards models were used to compare risk of persistent hypogonadism and castration at a median follow-up of 6.5 years (post-treatment to final T) (IQR: 4.3-9.1 years; Range: 1.0-19.2 years).
RESULTS: Of 1,981 patients receiving BT for clinically localized PCa, 1,053 met inclusion criteria. The 5-year freedom from hypogonadism rates were 92.4%, 88.9% and 87.0% for patients with no HT, 6 months and > 6 months of HT, respectively (10-year rates: 66.7%, 55.3%, 40.5%); 5-year freedom from castration rates were 99.2%, 98.0% and 98.4%, respectively (10-year rates: 97.9%, 95.5%, 90.9%). In multivariable analyses, number of months of HT (continuous variable, HR¼1.04, p¼.030) and BT with EBRT vs. BT alone (HR¼1.56, p¼.010) significantly increased the risk of persistent hypogonadism. Older age (HR¼1.04, p<.001) and diabetes (HR¼1.43, p¼.048) were also significant. Number of months of HT was the only variable which increased the risk of persistent castration (HR¼1.09, p¼.014).
CONCLUSIONS: EBRT is an independent risk factor for persistent hypogonadism among patients receiving BT for PCa. The mechanism of this finding needs to be elucidated, but may be secondary to scatter radiation during EBRT. Prolonged HT additionally increases the risk for persistent hypogonadism and castration. 
INTRODUCTION AND OBJECTIVES:
The exact role of pretreatment (baseline) total serum testosterone (BST) is still controversial in patients with prostate cancer (PCa) and conflicting results are reported in the literature. We assessed the impact of BST on the risk of biochemical failure (BF) in patients with PCa and treated with definitive radiation therapy (RT).
METHODS: The current study is a retrospective analysis of 360 prospective patients diagnosed with non-metastatic PCa between 2002 and 2014 and enrolled into seven different prospective multicentric phase II-III trials performed at our institution. All patients received definitive RT after initial diagnostic workup which included PSA and BST assessment. Patients were stratified according to hypogonadal (BST<11 nmol/L) vs. non-hypogonadal state (BST!11 nmol/L). The ability of this BST cut-off to predict BF was assessed in Kaplan-Meier analyses, as well as in univariable and multivariable Cox regression analyses. Internal validation of our findings was performed using bootstrap resampling with 10,000 replications.
RESULTS: The median (IQR) age at diagnosis was 71 years (65-74). Median (IQR) PSA was 7.7 ng/mL (5.6-12.1). Testosterone ranged from 0.7 to 28.9 nmol/L (mean: 11 nmol/L; median 10.2 nmol/L; IQR 8.3-13.0 nmol/L). The number of patients with BST < 11 nmol/L was 209 (58.0%), while a total of 151 patients had a BST ! 11 nmol/L
